Lee, Won-Chul
Reuben, Alexandre
Hu, Xin
McGranahan, Nicholas
Chen, Runzhe
Jalali, Ali
Negrao, Marcelo V.
Hubert, Shawna M.
Tang, Chad
Wu, Chia-Chin
Lucas, Anthony San
Roh, Whijae
Suda, Kenichi
Kim, Jihye
Tan, Aik-Choon
Peng, David H.
Lu, Wei
Tang, Ximing
Chow, Chi-Wan
Fujimoto, Junya
Behrens, Carmen
Kalhor, Neda
Fukumura, Kazutaka
Coyle, Marcus
Thornton, Rebecca
Gumbs, Curtis
Li, Jun
Wu, Chang-Jiun
Little, Latasha
Roarty, Emily
Song, Xingzhi
Lee, J. Jack
Sulman, Erik P.
Rao, Ganesh
Swisher, Stephen
Diao, Lixia
Wang, Jing
Heymach, John V.
Huse, Jason T.
Scheet, Paul
Wistuba, Ignacio I.
Gibbons, Don L.
Futreal, P. Andrew
Zhang, Jianhua
Gomez, Daniel
Zhang, Jianjun
Funding for this research was provided by:
Research Institute of Texas Multi-Investigator Research Award grant (RP160668)
MD Anderson Physician Scientist Award
TJ Martell Foundation and Conquer Cancer Foundation
Article History
Received: 6 May 2020
Accepted: 5 October 2020
First Online: 4 November 2020
Ethics approval and consent to participate
: Written informed consent for sample collection and analysis was obtained from all patients. The study was approved by the Institutional Review Board at the University of Texas MD Anderson Cancer Center (IRB number: PA13-0177) and conducted in accordance with the 1964 Helsinki Declaration and its later amendments.
: JZ reports research funding from Merck and Johnson & Johnson and personal fees from AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson GenePlus-Beijing Institute, OrigiMed, and Innovent outside the submitted work. KS reports research funding from Boehringer Ingelheim and Rain Therapeutics, and personal fees from AstraZeneca and Boehringer Ingelheim (all outside the submitted work). DLG has served on the scientific advisory committees for AstraZeneca, GlaxoSmithKline, Sanofi, and Janssen and has received research support from Janssen, Takeda, Ribon Therapeutics, Astellas, and AstraZeneca.